A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients (Q44341917)

2 December 2017

title

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients (English)

1 reference

2 December 2017

0 references

0 references

0 references

Joel Gelernter

5

0 references

David Oslin

1

object named as

David W Oslin

1 reference

2 December 2017

Helen Marie Pettinati

4

object named as

Helen Pettinati

1 reference

2 December 2017

3

Henry R Kranzler

1 reference

2 December 2017

Wade Berrettini

2

1 reference

2 December 2017

Joseph R Volpicelli

6

1 reference

2 December 2017

Charles P O'Brien

7

1 reference

2 December 2017

language of work or name

English

0 references

publication date

18 June 2003

1 reference

2 December 2017

published in

Neuropsychopharmacology

1 reference

2 December 2017

volume

28

1 reference

2 December 2017

issue

8

1 reference

2 December 2017

page(s)

1546-1552

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300219

2 December 2017

exact match

0 references

cites work

New methodologies for pharmacological treatment trials for alcohol dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Mu opioid receptor gene variants: lack of association with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Human mu opioid receptor gene polymorphisms and vulnerability to substance abuse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

A genetic association study of the mu opioid receptor and severe opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Pharmacogenomics and addiction to opiates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

The Fifth Edition of the Addiction Severity Index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Predicting treatment response to naltrexone: the influence of craving and family history

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

mu-opioid receptor variants and dopaminergic sensitivity in alcohol withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Uncontrollable events and alcohol drinking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Naltrexone blocks the post-shock increase of ethanol consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Effect of naltrexone on alcohol "high" in alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

Family history of alcoholism and hypothalamic opioidergic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

7 January 2021

Nonreplication of association between ?-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

7 January 2021

Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

7 January 2021

Naltrexone in the treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

7 January 2021

An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

7 January 2021

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

7 January 2021

Naltrexone as an adjunctive treatment for older patients with alcohol dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

7 January 2021

Reliability of a Timeline Method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300219

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300219

1 reference

2 December 2017

1 reference